<DOC>
	<DOCNO>NCT03035591</DOCNO>
	<brief_summary>This first-in-man study ass safety tolerability characterise pharmacokinetics ODM-207 .</brief_summary>
	<brief_title>ODM-207 Patients With Advance Solid Tumours</brief_title>
	<detailed_description />
	<criteria>Patients histologically cytologically confirm locally advanced metastatic cancer effective standard therapy exist refractory resistant conventional therapy Life expectancy &gt; 12 week Patient may either measurable nonmeasurable disease , must disease evaluated improvement progression ECOG performance status 0 1 History bleed disorder significant bleeding episode within 6 month prior study treatment Subjects receive anticoagulant medication durably inhibit platelet function ( 7day washout prior study treatment ) History current leptomeningeal brain metastasis spinal cord compression .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>